What is OS Therapies's pre-tax stock-based compensation cost?

OS Therapies (OSTX) reported pre-tax stock-based compensation cost of $1.44M in Q1 2026.

How has OS Therapies's pre-tax stock-based compensation cost changed year-over-year?

OS Therapies's pre-tax stock-based compensation cost increased by 52.5% year-over-year, from $941.28K to $1.44M.

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is OS Therapies's pre-tax stock-based compensation cost?: OS Therapies (OSTX) reported pre-tax stock-based compensation cost of $1.44M in Q1 2026.
How has OS Therapies's pre-tax stock-based compensation cost changed year-over-year?: OS Therapies's pre-tax stock-based compensation cost increased by 52.5% year-over-year, from $941.28K to $1.44M.